No Data
Berry Genomics: 2024 Annual Results Forecast
Berry Genomics (000710.SZ): A forecasted loss of 0.17 billion to -0.25 billion yuan for the year 2024.
Gelonghui, January 22 - Berry Genomics (000710.SZ) announced its performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 0.17 billion yuan to -0.25 billion yuan, a reduction in losses of 41.48% to 60.21% compared to the same period last year; the net income after deducting non-recurring gains and losses is expected to be a loss of 0.168 billion yuan to -0.248 billion yuan, a reduction in losses of 40.51% to 59.70% year-on-year; the basic EPS is expected to be a loss of 0.48 yuan/share to 0.71 yuan/share. During the reporting period, competition in the genetic testing market remains quite fierce, and facing a complex market environment, the company focuses on.
Little Excitement Around Berry Genomics Co.,Ltd's (SZSE:000710) Revenues As Shares Take 25% Pounding
PacBio Announces Shipment of Vega Systems to Berry Genomics
Express News | PacBio Ships First Vega Systems To Berry Genomics For Clinical Assay Development In Asian Markets, With Plans For NMPA Regulatory Approval And Over 50 Additional Units Committed
Berry Genomics (000710.SZ): Plans to invest in the Fuzhou Xintou Zhi Kairui Kang Venture Capital Fund.
On December 30, Gelonghui reports that Berry Genomics (000710.SZ) announced that its wholly-owned subsidiary Fujian Berry Health and Technology Co., Ltd. (referred to as "Berry Health and Technology") has signed the "Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership Agreement (Limited Partnership)" with Shanghai Zhikai Asset Management Co., Ltd., Fuzhou Xintou Venture Capital Co., Ltd., Shanghai Runda Medical Technology Co., Ltd., and Shanghai Fukai Ruikang Enterprise Management Consulting Partnership (Limited Partnership). Together, they will invest to establish the Fuzhou Xintou Zhikai Ruikang Venture Capital Fund Partnership (Limited Partnership), with a fundraising target scale of.
We Think Berry GenomicsLtd (SZSE:000710) Has A Fair Chunk Of Debt
